Vermilion ETF Pathfinder: Actionable ETF research & Ideas
Recent comments from Fed Chair Powell and the U.S.-China 90-day ceasefire agreement have drastically diminished (for now) concerns over two major sources of investor angst: (1) the pace of Fed tightenings and (2) trade policy. The S&P 500 is poised to open trading today near 2,817 resistance, a key level we are monitoring. The impending breakout - or breakdown below ~2,600 support, if resistance holds - will be key in determining where the market goes next.• Market internals improving. Key indicators monitoring internals/breadth provide reasons for optimism. The cap-weighted cyclicals (XLY) vs. staples (XLP) ratio suggests defensive leadership may be waning... see chart below. The percentage of stocks in the S&P 500 which are above their 50- and 200-day moving averages, and the index's advance-decline (A/D) line have all made higher lows, indicating a positive divergence considering the S&P 500 made a new price low on a closing basis (11/23)... see page 2.
• Big picture trends. High yield spreads are breaking out, raising the possibility of a recession or a deeper market decline. Continue to favor gold and base metals (GLD, IAU, DBB) within broad commodities. Our views on growth (IUSG) vs. value (IUSV) and large- (IVV) vs. small-caps (IJR) remain unchanged... see page 3.
• Sector rating changes: We are downgrading Technology (XLK) and upgrading Financials (XLF)... see pages 6 and 7.
• Actionable Industry ETFs: PPH, FCOM, REZ, and USMV... see page 10.
• EM and Int'l. Broad EM ETFs (EEM, VWO) are working through RS bottoms while RS for developed int'l ETFs (EFA, VEA) hits new all-time lows... see page 11.
• Actionable Int'l ETFs. MCHI, QAT, TUR, and EIS... see page 12.
Johnson & Johnson is a holding company engaged in the research and development, manufacture and sale of a range of products in the health care field. The company has three business segments: Consumer, which includes a range of products focused on personal healthcare used in the beauty, over-the-counter pharmaceutical, baby care, oral care, women's health and wound care markets; Pharmaceutical, which is focused on six therapeutic areas: immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension; and Medical Devices, which includes products used in the orthopaedic, surgery, interventional solutions, and eye health fields.
Zoetis is a holding company. Through its subsidiaries, the company is engaged in the discovery, development, manufacture and commercialization of animal health medicines, vaccines, and diagnostic products with a focus on both livestock and companion animals. The company operates in two segments: the United States and International. The company's main product categories are vaccines, anti-infectives, parasiticides, other pharmaceutical products, dermatology products, medicated feed additives, and animal health diagnostics. The company's other non-pharmaceutical product categories include nutritionals and agribusiness, as well as products and services including biodevices, genetic tests and precision livestock farming.
Vermilion Research delivers timely, actionable, and unique research inputs to professional investors. Our research strategists highlight securities which we believe are at major inflection points, based on our various proprietary technical indicators, and offer asymmetric risk/return profiles. We believe our research methodology, which is not limited by industry sector or market capitalization, enables us to deliver superior investment recommendations.
Our process begins by organizing all actively traded stocks into coherent sectors, then into logical industry groups. We then apply our proprietary relative strength tools to identify developing price trends. Once attractive trends are identified within a selected sectors or groups, we screen for individual stocks which we believe offer the best risk/reward profile. Vermilion offers U.S. and global equity market research products. Vermilion’s research team, which has received numerous awards and accolades, has a combined 70 year of experience in the analysis of investment securities.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.